SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-22-017040
Filing Date
2022-09-21
Accepted
2022-09-21 17:30:23
Documents
13
Period of Report
2022-09-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 35826
2 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 49988
  Complete submission text file 0001829126-22-017040.txt   269865

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ttnp-20220915.xsd EX-101.SCH 2965
4 XBRL LABEL FILE ttnp-20220915_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ttnp-20220915_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3616
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 221257442
SIC: 2836 Biological Products, (No Diagnostic Substances)